Literature DB >> 33593854

Interleukin-4 Induces the Release of Opioid Peptides from M1 Macrophages in Pathological Pain.

Dominika Labuz1, Melih Ö Celik2, Viola Seitz1, Halina Machelska2.   

Abstract

Interleukin-4 (IL-4) is an anti-inflammatory cytokine, which can be protective in inflammatory and neurologic disorders, and can alleviate pain. Classically, IL-4 diminishes pain by blocking the production of proinflammatory cytokines. Here, we uncovered that IL-4 induces acute antinociception by IL-4 receptor α (IL-4Rα)-dependent release of opioid peptides from M1 macrophages at injured nerves. As a model of pathologic pain, we used a chronic constriction injury (CCI) of the sciatic nerve in male mice. A single application of IL-4 at the injured nerves (14 d following CCI) attenuated mechanical hypersensitivity evaluated by von Frey filaments, which was reversed by co-injected antibody to IL-4Rα, antibodies to opioid peptides such as Met-enkephalin (ENK), β-endorphin and dynorphin A 1-17, and selective antagonists of δ-opioid, µ-opioid, and κ-opioid receptors. Injured nerves were predominately infiltrated by proinflammatory M1 macrophages and IL-4 did not change their numbers or the phenotype, assessed by flow cytometry and qRT-PCR, respectively. Macrophages isolated from damaged nerves by immunomagnetic separation (IMS) and stimulated with IL-4 dose dependently secreted all three opioid peptides measured by immunoassays. The IL-4-induced release of ENK was diminished by IL-4Rα antibody, intracellular Ca2+ chelator, and inhibitors of protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), and ryanodine receptors. Together, we identified a new opioid mechanism underlying the IL-4-induced antinociception that involves PKA-mediated, PI3K-mediated, ryanodine receptor-mediated, and intracellular Ca2+-mediated release from M1 macrophages of opioid peptides, which activate peripheral opioid receptors in injured tissue.SIGNIFICANCE STATEMENT Interleukin-4 (IL-4) is an anti-inflammatory cytokine, which can ameliorate pain. The IL-4-mediated effects are considered to mostly result from the inhibition of the production of proinflammatory mediators (e.g., IL-1β, tumor necrosis factor, prostaglandin E2). Here, we found that IL-4 injected at the injured nerves attenuates pain by releasing opioid peptides from the infiltrating macrophages in mice. The opioids were secreted by IL-4 in the intracellular Ca2+-dependent manner and activated local peripheral opioid receptors. These actions represent a novel mode of IL-4 action, since its releasing properties have not been so far reported. Importantly, our findings suggest that the IL-4-opioid system should be targeted in the peripheral damaged tissue, since this can be devoid of central and systemic side effects.
Copyright © 2021 the authors.

Entities:  

Keywords:  analgesia; antinociception; calcium-mediated release; neuropathic pain; opioids; peripheral opioid receptors

Year:  2021        PMID: 33593854      PMCID: PMC8018889          DOI: 10.1523/JNEUROSCI.3040-20.2021

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  50 in total

Review 1.  Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis.

Authors:  J A van Roon; F P Lafeber; J W Bijlsma
Journal:  Arthritis Rheum       Date:  2001-01

2.  Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease.

Authors:  Kamran Ghoreschi; Peter Thomas; Susanne Breit; Martin Dugas; Reinhard Mailhammer; Willem van Eden; Ruurd van der Zee; Tilo Biedermann; Jörg Prinz; Matthias Mack; Ulrich Mrowietz; Enno Christophers; Detlef Schlöndorff; Gerd Plewig; Christian A Sander; Martin Röcken
Journal:  Nat Med       Date:  2002-12-02       Impact factor: 53.440

3.  Leukocyte opioid receptors mediate analgesia via Ca(2+)-regulated release of opioid peptides.

Authors:  Melih Ö Celik; Dominika Labuz; Karen Henning; Melanie Busch-Dienstfertig; Claire Gaveriaux-Ruff; Brigitte L Kieffer; Andreas Zimmer; Halina Machelska
Journal:  Brain Behav Immun       Date:  2016-04-30       Impact factor: 7.217

4.  Pain control by CXCR2 ligands through Ca2+-regulated release of opioid peptides from polymorphonuclear cells.

Authors:  Heike L Rittner; Dominika Labuz; Michael Schaefer; Shaaban A Mousa; Stefan Schulz; Michael Schäfer; Christoph Stein; Alexander Brack
Journal:  FASEB J       Date:  2006-10-23       Impact factor: 5.191

5.  IL-4 induces M2 macrophages to produce sustained analgesia via opioids.

Authors:  Melih Ö Celik; Dominika Labuz; Jacqueline Keye; Rainer Glauben; Halina Machelska
Journal:  JCI Insight       Date:  2020-02-27

6.  Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation.

Authors:  Christina F Vogelaar; Shibajee Mandal; Steffen Lerch; Katharina Birkner; Jerome Birkenstock; Ulrike Bühler; Andrea Schnatz; Cedric S Raine; Stefan Bittner; Johannes Vogt; Jonathan Kipnis; Robert Nitsch; Frauke Zipp
Journal:  Sci Transl Med       Date:  2018-02-28       Impact factor: 17.956

7.  Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes.

Authors:  Y Sei; K L Gallagher; A S Basile
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

8.  IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts.

Authors:  Y Onoe; C Miyaura; T Kaminakayashiki; Y Nagai; K Noguchi; Q R Chen; H Seo; H Ohta; S Nozawa; I Kudo; T Suda
Journal:  J Immunol       Date:  1996-01-15       Impact factor: 5.422

9.  Differential expression of cytokines in painful and painless neuropathies.

Authors:  Nurcan Uçeyler; Jan P Rogausch; Klaus V Toyka; Claudia Sommer
Journal:  Neurology       Date:  2007-07-03       Impact factor: 9.910

10.  PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure.

Authors:  Steven Reiken; Alain Lacampagne; Hua Zhou; Aftab Kherani; Stephan E Lehnart; Chris Ward; Fannie Huang; Marta Gaburjakova; Jana Gaburjakova; Nora Rosemblit; Michelle S Warren; Kun-Lun He; Geng-Hua Yi; Jie Wang; Daniel Burkhoff; Guy Vassort; Andrew R Marks
Journal:  J Cell Biol       Date:  2003-03-10       Impact factor: 10.539

View more
  4 in total

1.  Effect of ancient Khorasan wheat on gut microbiota, inflammation, and short-chain fatty acid production in patients with fibromyalgia.

Authors:  Simone Baldi; Giuditta Pagliai; Monica Dinu; Leandro Di Gloria; Giulia Nannini; Lavinia Curini; Marco Pallecchi; Edda Russo; Elena Niccolai; Giovanna Danza; Stefano Benedettelli; Giovanna Ballerini; Barbara Colombini; Gianluca Bartolucci; Matteo Ramazzotti; Francesco Sofi; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2022-05-14       Impact factor: 5.374

2.  Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report.

Authors:  Nana Luo; Qiuyue Wang; Min Lei; Zhiyong Li; Tianhao Li; Pingsheng Hao
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-17

Review 3.  The Role of Neuro-Immune Interactions in Chronic Pain: Implications for Clinical Practice.

Authors:  Po-Yi Paul Su; Lingyi Zhang; Liangliang He; Na Zhao; Zhonghui Guan
Journal:  J Pain Res       Date:  2022-08-04       Impact factor: 2.832

4.  Amelioration of injury-induced tissue acidosis by a nonsteroidal analgesic attenuates antinociceptive effects of the pH-dependent opioid agonist NFEPP.

Authors:  Melih Ö Celik; Roger Negrete; Riccardo Di Rosso; Halina Machelska; Christoph Stein
Journal:  Sci Rep       Date:  2022-09-07       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.